IMpower010 – Exploratory analysis of DFS by KRAS status
The Phase III IMpower010 trial successfully demonstrated that the addition of atezolizumab following adjuvant platinum-based chemotherapy in patients with completely resected stage IB-IIIA non-small-cell lung cancer (NSCLC) led to improved disease-free survival outcomes. Among various oncogenic drivers in metastatic NSCLC, mutant KRAS stands out as the most prevalent. During ASCO 2023, Prof. Martin Reck from the Lung Clinic Grosshansdorf presented exploratory findings regarding disease-free survival outcomes based on the KRAS mutational status. The trial compared patients with tumours harbouring any type of mutant KRAS with those having KRAS wild-type (WT) tumours.
With the educational support of:
